An Introduction to Respiratory
Asthma is a chronic inflammatory disorder of the airwaves and one of the most common respiratory diseases. While the majority of cases can be controlled, severe asthma is associated with high risk of exacerbations and death. Severe asthma is categorised as T-helper type 2 (T2) high and T2 low. T2 high, also known as eosinophilic asthma, involves generation of cytokines including interleukin-4, −5 and −13. Recently, the management of severe eosinophilic asthma has been transformed by the development of monoclonal antibodies. Other allergic respiratory diseases include allergic rhinitis, which can be managed via symptomatic treatment with antihistamines, and allergy immunotherapy.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
Watch a panel of experts discuss the diagnosis of type 2 asthma, the rationale for biological therapy and emerging treatments.
- Recognize the importance of biomarkers to identify patients with type 2 asthma accurately and promptly
- Outline the pathologic pathways underlying type 2 asthma and the differing mechanisms of action of available biologic therapies
- Recall the latest data for biologic therapies in moderate-to-severe type 2 asthma
The role of eosinophils in physiology and disease: Is complete depletion of eosinophils the goal?
Watch Dr Enrico Heffler describe how eosinophilic inflammation can be targeted for the treatment of inflammatory respiratory diseases.
- Understand the dynamics of eosinophils across the human body in wellness and disease
- Discuss clinical scenarios in which eosinophilic therapy may be beneficial
- Recognize how new eosinophilic therapies offer promise for the future treatment of eosinophil-mediated diseases
Elliot Israel, ERS 2020 – Optimising Severe Asthma Management with Biologics
We spoke with Elliot Israel (Harvard Medical School, Boston, MA, USA) about the advances being made with biologics in the treatment of type 2 asthma. Questions How have biologic therapies transformed the management of severe asthma? (0:25) What have recent clinical trial data taught us about optimising the use of biologic therapies? (2:33) What are the […]
Vasileios Kouranos, ERS 2020 – Management of Cardiac Sarcoidosis
We were delighted to discuss with Vasileios Kouranos (Royal Brompton Hospital, London, UK) the current unmet need in the treatment of pulmonary and cardiac sarcoidosis alongside the therapeutic advances being made. Questions Could you give us a brief overview of pulmonary and cardiac sarcoidosis, their prevalence and prognosis? (0:22) What are the major unmet needs […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!